Although rabbit anti-T-lymphocyte globulin (ATLG) is largely used for the prevention of immune-mediated complications in patients given allogeneic haemopoietic stem-cell transplantation (HSCT) from an unrelated donor, the optimum dose of this drug in children is still undefined. We aimed to test whether a higher dose of ATLG was superior to a lower dose for prevention of grade II-IV acute graft-versus-host disease (GVHD).

中文翻译：

---

两种不同剂量的兔抗T淋巴细胞球蛋白预防从无关供体移植的血液系统恶性肿瘤患儿的移植物抗宿主病的功效：一项多中心，随机，开放标签的3期试验。

尽管兔抗T淋巴细胞球蛋白（ATLG）被广泛用于预防来自无关供体的同种异体造血干细胞移植（HSCT）患者的免疫介导并发症，但该药物在儿童中的最佳剂量仍不确定。我们旨在测试高剂量的ATLG是否优于低剂量的预防II-IV级急性移植物抗宿主病（GVHD）。